CA2107537A1 - Inhibition of tumor cell growth by administration of b7-transfected cells - Google Patents

Inhibition of tumor cell growth by administration of b7-transfected cells

Info

Publication number
CA2107537A1
CA2107537A1 CA002107537A CA2107537A CA2107537A1 CA 2107537 A1 CA2107537 A1 CA 2107537A1 CA 002107537 A CA002107537 A CA 002107537A CA 2107537 A CA2107537 A CA 2107537A CA 2107537 A1 CA2107537 A1 CA 2107537A1
Authority
CA
Canada
Prior art keywords
tumor cells
tumor cell
cell growth
inhibition
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002107537A
Other languages
French (fr)
Other versions
CA2107537C (en
Inventor
Lieping Chen
Ingegerd Hellstrom
Karl E. Hellstrom
Jeffrey A. Ledbetter
Peter S. Linsley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2107537A1 publication Critical patent/CA2107537A1/en
Application granted granted Critical
Publication of CA2107537C publication Critical patent/CA2107537C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Abstract

The present invention is directed to a method of inhibiting tumor cell growth.
Tumor cells from a pateint are recombinantly engineered to express the B7 surface protein and these cells are then readminsistered to the pateint. The presence of the B7 molecule on the tumor cell surface stimulates a broad immunologic response against both the B7-transfected and non-transfected tumor cells and results in the immunologic killing of localized and metastatic tumor cells. B7 transfection of the tumor cells, or cell membranes, serves as a stimulant to engender a potent immunologic response against the surface antigens present on the tumor cells.
CA002107537A 1992-10-02 1993-10-01 Inhibition of tumor cell growth by administration of b7-transfected cells Expired - Fee Related CA2107537C (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US95612392A 1992-10-02 1992-10-02
US07/956,123 1992-10-02
US610293A 1993-01-15 1993-01-15
US08/006,102 1993-01-15

Publications (2)

Publication Number Publication Date
CA2107537A1 true CA2107537A1 (en) 1994-04-03
CA2107537C CA2107537C (en) 2007-01-30

Family

ID=26675186

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002107537A Expired - Fee Related CA2107537C (en) 1992-10-02 1993-10-01 Inhibition of tumor cell growth by administration of b7-transfected cells

Country Status (11)

Country Link
US (1) US6183734B1 (en)
EP (1) EP0600591B1 (en)
JP (1) JP3837169B2 (en)
AT (1) ATE239073T1 (en)
AU (1) AU662450B2 (en)
CA (1) CA2107537C (en)
DE (1) DE69332921T2 (en)
DK (1) DK0600591T3 (en)
ES (1) ES2197147T3 (en)
MX (1) MX9306147A (en)
PT (1) PT600591E (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5056137A (en) * 1989-09-27 1991-10-08 Sills Richard R Method and apparatus for encoding and decoding signals
US5858776A (en) * 1993-11-03 1999-01-12 Repligen Corporation Tumor cells with increased immunogenicity and uses therefor
AU4647296A (en) * 1994-12-30 1996-07-24 Chiron Corporation Combination gene delivery vehicles
EP0733373A3 (en) * 1995-03-23 1999-04-28 Bristol-Myers Squibb Company Compositions and methods for increasing the immunogenicity of tumor cells by administration of B7 and CD2-transfected cells
DE19516040A1 (en) * 1995-05-04 1996-11-07 Boehringer Ingelheim Int Increasing immune response to tumour cells by increasing expression of TAP or LMP proteins
WO1996034952A1 (en) * 1995-05-04 1996-11-07 Boehringer Ingelheim International Gmbh Expression of tap and lmp in tumour cells
SE9604581D0 (en) * 1996-12-12 1996-12-12 Karolinska Innovations Ab An agent against cancer and virus infections
US6077833A (en) * 1996-12-31 2000-06-20 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US7235653B2 (en) 1996-12-31 2007-06-26 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US6319906B1 (en) 1996-12-31 2001-11-20 Isis Pharmaceuticals Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US6682741B1 (en) * 1998-06-10 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services β2 microglobulin fusion proteins and high affinity variants
AUPQ755300A0 (en) * 2000-05-17 2000-06-08 Monash University Immune potentiating compositions
US7780993B2 (en) * 2001-09-07 2010-08-24 Yeda Research And Development Co. Ltd. Therapeutic transplantation using developing, human or porcine, renal or hepatic, grafts
US20040136972A1 (en) * 2001-09-07 2004-07-15 Yeda Research And Development Co. Ltd. Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
US20030096016A1 (en) * 2001-09-07 2003-05-22 Yeda Research And Development Co. Ltd. Methods of kidney transplantation utilizing developing nephric tissue
CA2485098A1 (en) * 2002-05-02 2003-11-13 University Of Connecticut Health Center Use of heat shock proteins to enhance efficacy of antibody therapeutics
IL165425A0 (en) * 2004-11-28 2006-01-15 Yeda Res & Dev Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
CA2463487A1 (en) * 2003-04-28 2004-10-28 Auckland Uniservices Limited Tumours treating combinations, compositions and methods
CA2463464A1 (en) * 2003-04-28 2004-10-28 Auckland Uniservices Limited Methods of treatment and compositions therefor
US7960355B2 (en) 2003-05-23 2011-06-14 Isis Pharmaceuticals, Inc. Compositions and methods for the modulation of the expression of B7 protein
US7897582B2 (en) 2003-05-23 2011-03-01 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000092A1 (en) * 1990-07-02 1992-01-09 Bristol-Myers Squibb Company Ligand for cd28 receptor on b cells and methods

Also Published As

Publication number Publication date
EP0600591B1 (en) 2003-05-02
ATE239073T1 (en) 2003-05-15
AU4877293A (en) 1994-04-14
EP0600591A3 (en) 1995-03-01
AU662450B2 (en) 1995-08-31
JPH0769928A (en) 1995-03-14
MX9306147A (en) 1994-06-30
CA2107537C (en) 2007-01-30
US6183734B1 (en) 2001-02-06
DE69332921D1 (en) 2003-06-05
ES2197147T3 (en) 2004-01-01
DE69332921T2 (en) 2004-05-19
DK0600591T3 (en) 2003-08-25
PT600591E (en) 2003-09-30
JP3837169B2 (en) 2006-10-25
EP0600591A2 (en) 1994-06-08

Similar Documents

Publication Publication Date Title
CA2107537A1 (en) Inhibition of tumor cell growth by administration of b7-transfected cells
CA2105552A1 (en) Soluble ligands for cd40
CA2315230A1 (en) Anti-cryptococcal peptides
EP0248594A3 (en) Pharmacologically active 1,5-diaryl-3-substituted-pyrazopharmacologically active 1,5-diaryl-3-substituted-pyrazoles and method for synthesizing the same les and method for synthesizing the same
CA2045594A1 (en) Immunogenic compositions against gastrin peptides
IT1196484B (en) YEAST EXPRESSION AND SECRETION VECTOR, USEFUL FOR THE PREPARATION OF HETEROLOGICAL PROTEINS
NO974693L (en) Pharmaceutical preparation containing N-chlorophenylcarbamates, N-chlorophenylthiocarbamates and N-phosphonoglycine derivatives to inhibit mammalian cancer and virus growth
BR9712556A (en) Plasmid, pharmaceutical composition, and, process of immunizing an individual against an antigen
WO1999063063A8 (en) Cellular proteins which mediate herpesvirus entry
EP0684260A3 (en) Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof.
AU7237391A (en) Carrier-bound recombinant protein, process for producing it and its use as an immunogen and vaccine
EP0209543A4 (en) Peptide fragments of human apolipoprotein, type-specific antibodies and methods of use.
EP0161007A3 (en) Retro - inverso c-terminal hexapeptide analogues of substance p
AU7440087A (en) Process for isolating and purifying p. falciparum cs protein vaccine expressed in recombinant e. coli
EP0800828A4 (en) Transmucosal preparation
EP0733373A3 (en) Compositions and methods for increasing the immunogenicity of tumor cells by administration of B7 and CD2-transfected cells
DK0938329T3 (en) Immunogenic TLP composition
HUP9700074A2 (en) Low molecular yeast active substance extract and process for preparing the same
IT1218692B (en) MICROBIOLOGICAL PROCEDURE FOR THE PREPARATION OF 9 ALPHA-HYDROXY-4-ANDROSTENE-3.17 DIONE
AU673344B2 (en) Vaccines based on streptokinase
DE69709891T2 (en) COMPOSITION CONTAINING CHITOSAN
IT1164363B (en) THERAPEUTIC PROCEDURE FOR THE USE OF EMBORNED LIPOSOMES FRUCTOSE 1.6 DIPHOSPHATE AND PROCEDURE FOR THE PREPARATION OF THE SAME
FR2733230B1 (en) NOVEL ORNITHIN DERIVATIVES, PREPARATION METHOD, USE AND COMPOSITION COMPRISING THE SAME
AU8501191A (en) Cross-reactive influenza a immunization
Green Detailed sedimentology of the Bowser Lake group, northern Bowser basin, north-central British Columbia.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed